Cargando…

Optimal timing of chemotherapy and cystectomy

Radical cystectomy with pelvic lymphadenectomy is the standard treatment for muscle-invasive bladder cancer. However, the high recurrence rates and high death rate from metastases after radical cystectomy for locally advanced bladder cancer emphasize the high risk of occult distant disease. To impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Karam, Jose A, Kamat, Ashish M
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950042/
https://www.ncbi.nlm.nih.gov/pubmed/20948836
http://dx.doi.org/10.3410/M2-48
_version_ 1782187617713913856
author Karam, Jose A
Kamat, Ashish M
author_facet Karam, Jose A
Kamat, Ashish M
author_sort Karam, Jose A
collection PubMed
description Radical cystectomy with pelvic lymphadenectomy is the standard treatment for muscle-invasive bladder cancer. However, the high recurrence rates and high death rate from metastases after radical cystectomy for locally advanced bladder cancer emphasize the high risk of occult distant disease. To improve patient survival, multimodal therapy whereby chemotherapy and surgery are used in concert with each other is necessary. The preponderance of data suggests that neoadjuvant chemotherapy offers patients a clear - albeit small - survival advantage, whereas the data for adjuvant chemotherapy are less convincing. Currently, trials to improve the results of such neoadjuvant therapy using biologic targets in conjunction with cytotoxic regimens are under way.
format Text
id pubmed-2950042
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29500422010-10-14 Optimal timing of chemotherapy and cystectomy Karam, Jose A Kamat, Ashish M F1000 Med Rep Review Article Radical cystectomy with pelvic lymphadenectomy is the standard treatment for muscle-invasive bladder cancer. However, the high recurrence rates and high death rate from metastases after radical cystectomy for locally advanced bladder cancer emphasize the high risk of occult distant disease. To improve patient survival, multimodal therapy whereby chemotherapy and surgery are used in concert with each other is necessary. The preponderance of data suggests that neoadjuvant chemotherapy offers patients a clear - albeit small - survival advantage, whereas the data for adjuvant chemotherapy are less convincing. Currently, trials to improve the results of such neoadjuvant therapy using biologic targets in conjunction with cytotoxic regimens are under way. Medicine Reports Ltd 2010-06-23 /pmc/articles/PMC2950042/ /pubmed/20948836 http://dx.doi.org/10.3410/M2-48 Text en © 2010 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Karam, Jose A
Kamat, Ashish M
Optimal timing of chemotherapy and cystectomy
title Optimal timing of chemotherapy and cystectomy
title_full Optimal timing of chemotherapy and cystectomy
title_fullStr Optimal timing of chemotherapy and cystectomy
title_full_unstemmed Optimal timing of chemotherapy and cystectomy
title_short Optimal timing of chemotherapy and cystectomy
title_sort optimal timing of chemotherapy and cystectomy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950042/
https://www.ncbi.nlm.nih.gov/pubmed/20948836
http://dx.doi.org/10.3410/M2-48
work_keys_str_mv AT karamjosea optimaltimingofchemotherapyandcystectomy
AT kamatashishm optimaltimingofchemotherapyandcystectomy